C3H mice were immunized with MH134tumors modified with two different chemicals, DEPC and TNBS,and the tumor-neutralizing activities of the spleen cells were examined after separating the cells by a Nylon-wool column, plastic dish, or treatment with specific antibodies (anti-mouse IgG and anti-mouse 0 sera). The effector cells induced in mice by immunization with TNBS-treated tumors were T cells. In contrast, in the case of tumors modified with DEPC,macrophages were the major effector cells. The effects of chemical modification on the solubilization of cell surface proteins was also examined. DEPCinhibited solubilization of specific proteins from tumor cell surfaces, while TNBSdid not have such an effect on the solubilization of proteins. These results indicate that the antitumor response in mice primed with DEPC-modified tumor is different from the case of TNBS-modified tumors, and that the immunological significance of chemical modification with DEPCis supposedly due to the stabilization of antigenic proteins on the tumor cell surface. are efficient not only as chemical modifiers to label amino groups,7) but also in introducing hapten groups into carrier proteins.8) Accordingly, an attempt was made to apply these chemicals to the modification of tumors to raise immunity to tumor antigens, and it was found that 1615 TNBS was an effective reagent for inducing MH134 tumor resistance in syngeneic mice. This was fortunate to elucidate the antitumor response mechanisms in mice induced by immunization with DEPC-treated tumors, because several papers have reported on the antitumor response mechanism by a host against TNP-coupled protein or TNP-conjugated tumors.9~n) In this work, we have compared the effector cells that can reject the tumor development in mice immunized with DEPC-treated tumors and those in mice immunized with TNBS-treated tumors, and have described the immunological significance of DEPCon the modification of tumors.
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Materials and Methods
Materials. C3Hand DBA/2mice were purchased from Charles River Japan, Inc. The MH134tumor was kindly supplied by Prof. Z. Sato, Okayama Univ., and was maintained by serial transplantation in syngenic C3H mice. L1210 leukemia was kindly supplied by the Yositomi Pharmaceutical Co., and was maintained. DEPCwas a gift from Takeda Pharmaceutical Industries, Ltd. TNBS was from Wako Pure Chemical Industry, Ltd. Anti-mouse IgG and anti-mouse 6 sera (AKR anti-C3H) were from Bionetics Co. Alkaline phosphatase-conjugated goat antimouse IgG was from Bio-Rad Laboratories. SDSat 30°C overnight. The extent of trinitrophenylation reached a plateau after 120min of reaction.
Immunization of mice. C3Hmice were immunized intraperitoneally with 3x lO6 cells per mouse of DEPCtreated AcOH-MH134or TNBS-treated AcOH-MH134. Immunization was repeated four times as described previously.6* Ten days after the last immunization, the mice were challenged with live MH134 (105 cells/mouse) intraperitoneally.
The survivors without tumors received a further challenge of the same dose of cells on day 30. The mice which completely rejected the second challenge were regarded as tumor resistant mice.
Lymphocyte preparation from spleens. Spleens were removed from mice immunized intraperitoneally four times with TNBS-treated AcOH-MH134 or DEPC-treated AcOH-MH134. Dispersed spleen cells were washed twice with 199 medium and finally suspended in the same 199 medium (108 cells/ml). Cells were separated by passing the cells through a Nylon-wool column by the method ofJulis et al. Tris-HCl, pH 7.4, containing 500 mMNaCl) and incubated with TBS containing 1% gelation for 1 hr. The sheet was further incubated for 3 hr with primary antiserum diluted 1 : 100 in TBS containing 1% gelatin and was washed twice with TBS, and TBS containing 0.5% Triton X-100. The primary antiserum was prepared from C3H mine immunized four times with DEPC-treated AcOH-MH134. The nitrocellulose sheet was incubated for 1hr with alkaline phosphatase-conjugated goat anti-mouse IgG. The sheet was developed with BCIP (5-bromo-4-chloro-3-indolephosphate)/NBT (nitroblue tetrazolium) alkaline phosphatase, as described in the Bio-Rad instruction manual.
Results and Discussion
The immunogenicity of tumor antigens is not strong enough to establish immunity resulting in rejection of that tumor from the host.19) Therefore, several attempts have been madeto raise immunity to tumor antigents by provinding artificial antigenic determinants.
The chemical reagents such as TNBS, DNFB, and Dans-Cl are often used to introduce hap- Table I shows the effects of TNBS-treated AcOH-MH134 on the induction of resistance against MH134. Immunization with TNBS-treated AcOH-MH134in-duced a resistance to the live MH134 cell challenge, but the intermediate level (approximately 40%) of trinitrophenylation was a more adequate immunogen, suggesting that some parts of the tumor-specific transplantation antigens are required to remain intact to raise immunity to tumors. We also observed that the spleen cells from the mice which were immunized four times with TNBS-treated AcOH-MH134 had a tumor-neutralizing activity to MH134in vivo, but the serum obtained from the sametumor-resistant mice was unable to prevent tumor growth. Kitagawa et al.19'20) reported that the effector T-cells for preventing tumor growth were induced in mice by pre-immunization with hapten-coupled mouse-y-globulin or haptencoupled tuberculin, followed by immunization with hapten-coupled tumors. Based on these experimental data, we examined the effector cells in mice which were immunized with TNBS-treated AcOH-MH134 and DEPCtreated AcOH-MH134.6) Figure 1 shows the tumor-neutralization activity of spleen cells from mice immunized with TNBS-treated AcOH-134. The spleen cells which passed through a Nylon-wool column prevented MH134 tumor growth. In contrast, strong tumor-neutralizing activity was detected in the Nylon-wool adhered spleen cells when mice were immunized with DEPC-treated AcOH-MH134 (Fig. 2) . This shows that macrophages or B cells are involved in the prevention of tumor growth. Therefore, the effector cells were further characterized by treatment with specific antibodies. Nylon-wool-nonadherent cells were incubated with anti-mouse 9 serum. As T cells are en- gel. Figure 4 shows the electrophoresis pattern of solubilized proteins from MH134. The electrophoresis patterns of native MH134 was similar to that for AcOH-MH134,except that high molecular mass protein bands with relative molecular masses of 215kDa and 195kDa were faint or absent in the cells treated with DEPC(arrows indicate the po- (Fig. 6 ). Figure 7 shows the immunoblotting analysis of the cell surface tumor antigens. Three intensive bands with relative molecular masses of 215kDa, 80kDa, and 62kDa, and three weak bands with relative molecular masses of 105kDa, 86kDa, and 70kDa were observed, suggesting that the MH134 cells are expressing several tumor specific transplantation antigens on their cell surface. But that all antigens are in fact involved in the induction of tumor resistance is not clear, since the humoral antibodies from mice immunized with DEPCtreated AcOH-MH134 failed to reject the transplanted tumor growth. Nevertheless, the 215kDa protein expressed on MH134 cell surface may be an important immunogenic protein for tumor immunity in C3Hmice.
On the rejection of transplanted tumor cells, The results in Fig. 1 and Table II demonstrated that the cytotoxic effector cells induced with TNBS-treated AcOH-MH134 were T cells. Contrary to this, in the case of the immunization of mice with DEPCtreated AcOH-MH134,macrophages were identified as the cytotoxic effector cells (Fig. 2 and Fig. 3 ). Macrophages were reported to kill the tumor cells in an antibody-dependent manner. So we supposed that the B cells remaining in the macrophage fractions secreted antibodies to tumor antigens or macrophagescontained immunoglobulinmolecules on the cell surface specific to tumor antigens. While the immunization of mice with DEPC-treated AcOH-MH134 induced serum antibodies to tumor cells, it could not induce cytotoxic T cells to MH134. This suggested that T cells could not recognize the tumor-specific antigens expressed on the immunized DEPCtreated AcOH-MH1 34. Insolubilization of certain cell surface proteins of MH134cells with Proteins extracted from untreated MH134 cells were electrophoresed by SDS-polyacrylamide gel electrophoresis. The proteins separated were transferred onto nitrocellulose sheet and then the tumor specific transplantation antigens were stained with antiserum from C3Hmouse immunized with DEPC-treated AcOH-MH134.
DEPC treatment ( 
